Zimmer Biomet (NYSE:ZBH) Posts Earnings Results, Beats Expectations By $0.01 EPS

Zimmer Biomet (NYSE:ZBH) released its earnings results on Thursday. The medical equipment provider reported $2.31 earnings per share for the quarter, beating analysts’ consensus estimates of $2.30 by $0.01, RTT News reports. Zimmer Biomet had a net margin of 14.27% and a return on equity of 12.95%. During the same period in the previous year, the business earned $2.20 EPS. Zimmer Biomet updated its FY 2025 guidance to 8.150-8.350 EPS.

Zimmer Biomet Stock Performance

NYSE:ZBH traded down $3.59 during trading hours on Thursday, reaching $104.66. The company had a trading volume of 1,526,851 shares, compared to its average volume of 1,703,455. The company has a current ratio of 1.36, a quick ratio of 0.70 and a debt-to-equity ratio of 0.38. Zimmer Biomet has a 52 week low of $100.67 and a 52 week high of $133.90. The firm has a market cap of $20.83 billion, a price-to-earnings ratio of 19.95, a PEG ratio of 1.88 and a beta of 1.02. The firm’s 50 day moving average price is $107.75 and its 200-day moving average price is $108.20.

Zimmer Biomet Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, January 31st. Stockholders of record on Monday, December 30th were issued a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.92%. The ex-dividend date was Monday, December 30th. Zimmer Biomet’s payout ratio is presently 18.25%.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on ZBH shares. JPMorgan Chase & Co. upgraded Zimmer Biomet from a “neutral” rating to an “overweight” rating and increased their price target for the stock from $125.00 to $128.00 in a research note on Tuesday, December 17th. Needham & Company LLC reaffirmed a “hold” rating on shares of Zimmer Biomet in a report on Wednesday, January 29th. Truist Financial upped their price objective on shares of Zimmer Biomet from $117.00 to $118.00 and gave the stock a “hold” rating in a research report on Wednesday, December 18th. Stifel Nicolaus lifted their price target on Zimmer Biomet from $130.00 to $138.00 and gave the stock a “buy” rating in a research note on Thursday, January 23rd. Finally, Oppenheimer decreased their target price on shares of Zimmer Biomet from $145.00 to $135.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 15th. Two investment analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $124.11.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.